Medable

02/03/2026

It's been non-stop for Team Medable at so far! Stop by booth #806 if you're curious about 'big TMF energy' 😜.

Our AI agents enable highly skilled professionals to perform more strategic work so they can truly move the needle on clinical development.

We'll show you how!
________

02/02/2026

What if “day one” actually meant progress?

Standardized decisions and pre-built patient & site trial experiences let teams align faster, sign off sooner, and avoid the slow starts that derail studies before they begin.

Hear more from Asad Khan below!
________

01/30/2026

Vintage works in fashion. But it’s not a good look for your eCOA. ❌

What once passed as “digital” no longer meets the demands of modern trials. Today’s study participants need technology built for speed, flexibility, and ease of use—not systems designed for another era.

Everest Group’s recognition of Medable as a Leader in the inaugural eCOA Products PEAK Matrix reflects this shift: eCOA has moved from a supporting role to a strategic foundation for how trials are designed, launched, and run.

Learn more here: https://www.medable.com/knowledge-center/blog-everest-analysis-how-medable-ecoa-solves-speed-patient-experience-and-customer-needs
________

01/29/2026

Everyone wants faster trials, but few are really fixing what slows them down.
In this Q&A, Andrew Mackinnon reveals how Agent Studio, featuring CRA and TMF agents, is engineered to cut study timelines, reduce administrative burden, and unlock parallel ex*****on across larger networks, all without compromising data integrity or compliance.

Read here: https://www.clinicaltrialvanguard.com/executiveinterviews/agentic-ai-for-clinical-trials-medables-roadmap-to-speed-and-scale/
________

In this in-depth Q&A, we sit with Andrew Mackinnon to explore Medable’s agentic AI platform and its first agents...

01/28/2026

📣 Today, Medable launches an AI agent for research sites to reduce burden and assist principal investigators in the oversight and monitoring of eCOA data. Released just after Medable’s TMF and CRA agents, the PI Summary Agent continues the rapid rollout of function-specific agentic capabilities designed to maximize investigator capacity and accelerate site workflows.

👉 Learn more here: https://www.medable.com/newsroom/medable-introduces-ai-agent-to-reduce-burden-at-research-sites-by-assisting-principal-investigators-with-oversight-of-ecoa-data
________

01/27/2026

As 2026 gets underway, biotech and pharma leaders make their predictions for the hottest trends that will shape the industry this year. Consistent with the pattern of the last couple of years, the focus remains on artificial intelligence (AI).

While many companies have shown the promise of AI in drug discovery and diagnostics, these leaders see AI taking on an even larger role in 2026—accelerating manufacturing, clinical trial data analysis, the regulatory path to drug approvals, and more.

Get the insights here: https://www.the-scientist.com/advances-in-digital-and-ai-solutions-for-drug-discovery-and-development-73273
________

Explore how the latest technologies help researchers handle vast data sets, overcome workflow bottlenecks, and accelerate biopharma breakthroughs.

01/26/2026

Building your own clinical AI looks simple on the surface. A slick demo. A fast pilot. A sense of momentum.

What lies below the waterline is everything that breaks down: validation, compliance, integration, auditability, & trust.

Those are the parts that prototypes don't show.

01/22/2026

Forget AI pilots that never scale. This podcast episode goes inside real clinical trials, where agentic AI is accelerating timelines, reducing operational drag, and changing how research teams work at the portfolio level.

Our CEO, Dr. Michelle Longmire, explains what’s real, what’s safe, and what’s next here: https://open.spotify.com/episode/0AEBuxUYDsRz7wjWT5wtIW

The Beat · Episode

01/21/2026

Better compliance isn’t about nagging harder. It’s about deploying studies patients can actually follow.

Medable eCOA builds adherence into your trials, so data shows up complete, on time, and inspection-ready.

Hear the insights from our CCO Alison Holland below!
________

01/20/2026

Patients are increasingly “shopping” for health on their terms, and as preventive care spending is far lower than curative care, could the uptake of a more personalized approach result in healthier, better choices?

This session at the World Economic Forum, moderated by Medable CEO Dr. Michelle Longmire, will explore how industries can advance prevention, extend health-spans, and manage chronic disease more effectively.

Don’t miss the chance to follow the discussions here: wef.ch/wef26
________

01/16/2026

felt different.
Less talk about surviving the market. More focus on getting things done.

From AI taking on the heavy lifting in clinical operations to renewed confidence across biopharma pipelines, the industry is shifting from recovery to results.

In case you missed it, here’s what we saw, heard, and learned on the ground: https://www.medable.com/knowledge-center/blog-what-happened-at-jpm-2026
________

01/15/2026

AI is transforming drug discovery, but clinical trials are still 80–90% manual.
That disconnect is why breakthroughs stall before they reach patients.

In this interview from , Medable CEO Dr. Michelle Longmire explains how agentic AI removes the tactical bottlenecks in trials, redirects resources to true unmet needs, and unlocks precision medicine at scale.

Read here: https://www.pharmtech.com/view/the-transformative-potential-of-ai-to-enhance-patient-treatment
_______

AI and machine learning may be the ideal tools to evaluate patient data and predict ideal treatment options.